|
1
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nilubol N and Kebebew E: Should small
papillary thyroid cancer be observed? A population-based study.
Cancer. 121:1017–1024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE and
Rosenthal MS: American Thyroid Association Anaplastic Thyroid
Cancer Guidelines Taskforce: American Thyroid Association
guidelines for management of patients with anaplastic thyroid
cancer. Thyroid. 22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kebebew E, Greenspan FS, Clark OH, Woeber
KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome
and prognostic factors. Cancer. 103:1330–1335. 2005.
|
|
5
|
McIver B, Hay ID, Giuffrida DF, Dvorak CE,
Grant CS, Thompson GB, van Heerden JA and Goellner JR: Anaplastic
thyroid carcinoma: a 50-year experience at a single institution.
Surgery. 130:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sugitani I, Miyauchi A, Sugino K, Okamoto
T, Yoshida A and Suzuki S: Prognostic factors and treatment
outcomes for anaplastic thyroid carcinoma: ATC Research Consortium
of Japan cohort study of 677 patients. World J Surg. 36:1247–1254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neff RL, Farrar WB, Kloos RT and Burman
KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am.
37:525–538. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Tward JD, Shrieve DC and Hitchcock
YJ: Surgery andradiotherapy improves survival in patients with
anaplastic thyroid carcinoma: Analysis of the surveillance,
epidemiology, and end results 1983–2002. Am J Clin Oncol.
31:460–464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
ONeill JP and Shaha AR: Anaplastic thyroid
cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ranganathan P, Weaver KL and Capobianco
AJ: Notch signalling in solid tumours: A little bit of everything
but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol l8. 97–106. 2011. View Article : Google Scholar
|
|
12
|
Kopan R and Ilagan MX: The canonical Notch
signaling pathway: unfolding the activation mechanism. Cell.
137:216–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roy M, Pear WS and Aster JC: The
multifaceted role of Notch in cancer. Curr Opin Genet Dev.
17:52–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kunnimalaiyaan M and Chen H: Tumor
suppressor role of Notch-1 signaling in neuroendocrine tumors.
Oncologist. 12:535–542. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao X, Ning L and Chen H: Notch1 mediates
growth suppression of papillary and follicular thyroid cancer cells
by histone deacetylase inhibitors. Mol Cancer Ther. 8:350–356.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferretti E, Tosi E, Po A, Scipioni A,
Morisi R, Espinola MS, Russo D, Durante C, Schlumberger M,
Screpanti I, et al: Notch signaling is involved in expression of
thyrocyte differentiation markers and is down-regulated in thyroid
tumors. J Clin Endocrinol Metab. 93:4080–4087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oswald F, Kostezka U, Astrahantseff K,
Bourteele S, Dillinger K, Zechner U, Ludwig L, Wilda M, Hameister
H, Knöchel W, et al: SHARP is a novel component of the
Notch/RBP-Jkappa signalling pathway. EMBO J. 21:5417–5426. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Federico M and Bagella L: Histone
deacetylase inhibitors in the treatment of hematological
malignancies and solid tumors. J Biomed Biotechnol.
2011:4756412011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng J, Zhang HH, Zhou CX, Li C, Zhang F
and Mei QB: The histone deacetylase inhibitor trichostatin A
induces cell cycle arrest and apoptosis in colorectal cancer cells
via p53-dependent and -independent pathways. Oncol Rep. 28:384–388.
2012.PubMed/NCBI
|
|
20
|
Phan T, Yu XM, Kunnimalaiyaan M and Chen
H: Antiproliferative effect of chrysin on anaplastic thyroid
cancer. J Surg Res. 170:84–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sippel RS, Carpenter JE, Kunnimalaiyaan M,
Lagerholm S and Chen H: Raf-1 activation suppresses neuroendocrine
marker and hormone levels in human gastrointestinal carcinoid
cells. Am J Physiol Gastrointest Liver Physiol. 285:G245–G254.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA
and Chen H: Overexpression of the NOTCH1 intracellular domain
inhibits cell proliferation and alters the neuroendocrine phenotype
of medullary thyroid cancer cells. J Biol Chem. 281:39819–39830.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kao HY, Ordentlich P, Koyano-Nakagawa N,
Tang Z, Downes M, Kintner CR, Evans RM and Kadesch T: A histone
deacetylase corepressor complex regulates the Notch signal
transduction pathway. Genes Dev. 12:2269–2277. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Platta CS, Greenblatt DY, Kunnimalaiyaan M
and Chen H: Valproic acid induces Notch1 signaling in small cell
lung cancer cells. J Surg Res. 148:31–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adler JT, Hottinger DG, Kunnimalaiyaan M
and Chen H: Histone deacetylase inhibitors upregulate Notch-1 and
inhibit growth in pheochromocytoma cells. Surgery. 144:956–961.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ning L, Greenblatt DY, Kunnimalaiyaan M
and Chen H: Suberoyl bis-hydroxamic acid activates Notch-1
signaling and induces apoptosis in medullary thyroid carcinoma
cells. Oncologist. 13:98–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greenblatt DY, Cayo MA, Adler JT, Ning L,
Haymart MR, Kunnimalaiyaan M and Chen H: Valproic acid activates
Notch1 signaling and induces apoptosis in medullary thyroid cancer
cells. Ann Surg. 247:1036–1040. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ebrahimi M and Shamabadi N: Endocrine
disrupting chemicals in pesticides and herbicide in Fars Province,
Iran. Pak J Biol Sci. 10:3175–3179. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stockhausen MT, Sjölund J, Manetopoulos C
and Axelson H: Effects of the histone deacetylase inhibitor
valproic acid on Notch signalling in human neuroblastoma cells. Br
J Cancer. 92:751–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SB, Chae GW, Lee J, Park J, Tak H,
Chung JH, Park TG, Ahn JK and Joe CO: Activated Notch1 interacts
with p53 to inhibit its phosphorylation and transactivation. Cell
Death Differ. 14:982–991. 2007.PubMed/NCBI
|
|
31
|
Rooman I, De Medts N, Baeyens L, Lardon J,
De Breuck S, Heimberg H and Bouwens L: Expression of the Notch
signalingpathway and effect on exocrine cell proliferation in adult
rat pancreas. Am J Pathol. 169:1206–1214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kolev V, Kacer D, Trifonova R, Small D,
Duarte M, Soldi R, Graziani I, Sideleva O, Larman B, Maciag T, et
al: The intracellular domain of Notch ligand Delta1 induces cell
growth arrest. FEBS Lett. 579:5798–5802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Devine T and Dai MS: Targeting the
ubiquitin-mediated proteasome degradation of p53 for cancer
therapy. Curr Pharm Des. 19:3248–3262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shan X, Fu YS, Aziz F, Wang XQ, Yan Q and
Liu JW: Ginsenoside Rg3 inhibits melanoma cell proliferation
through down-regulation of histone deacetylase 3 (HDAC3) and
increase of p53 acetylation. PLoS One. 9:e1154012014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qi R, An H, Yu Y, Zhang M, Liu S, Xu H,
Guo Z, Cheng T and Cao X: Notch1 signaling inhibits growth of human
hepatocellular carcinoma through induction of cell cycle arrest and
apoptosis. Cancer Res. 63:8323–8329. 2003.PubMed/NCBI
|
|
36
|
Talora C, Cialfi S, Segatto O, Morrone S,
Kim Choi J, Frati L, Dotto G Paolo, Gulino A and Screpanti I:
Constitutively active Notch1 induces growth arrest of HPV-positive
cervical cancer cells via separate signaling pathways. Exp Cell
Res. 305:343–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang X, Klein R, Tian X, Cheng HT, Kopan R
and Shen J: Notch activation induces apoptosis in neural progenitor
cells through a p53-dependent pathway. Dev Biol. 269:81–94. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oswald F, Täuber B, Dobner T, Bourteele S,
Kostezka U, Adler G, Liptay S and Schmid RM: p300 acts as a
transcriptional coactivator for mammalian Notch-1. Mol Cell Biol.
21:7761–7774. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roperch JP, Alvaro V, Prieur S, Tuynder M,
Nemani M, Lethrosne F, Piouffre L, Gendron MC, Israeli D, Dausset
J, et al: Inhibition of presenilin 1 expression is promoted by p53
and p21WAF-1 and results in apoptosis and tumor suppression. Nat
Med. 4:835–838. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sasaki Y, Ishida S, Morimoto I, Yamashita
T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y and Tokino T:
The p53 family member genes are involved in the Notch signal
pathway. J Biol Chem. 277:719–724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nair P, Somasundaram K and Krishna S:
Activated Notch1 inhibits p53-induced apoptosis and sustains
transformation by human papillomavirus type 16 E6 and E7 oncogenes
through a PI3K-PKB/Akt-dependent pathway. J Virol. 77:7106–7112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mungamuri SK, Yang X, Thor AD and
Somasundaram K: Survival signaling by Notch1: mammalian target of
rapamycin (mTOR)-dependent inhibition of p53. Cancer Res.
66:4715–4724. 2006. View Article : Google Scholar : PubMed/NCBI
|
